BAD HOMBURG (dpa-AFX) - The medical group and hospital operator Fresenius has raised its forecast thanks to good business with products for clinical nutrition, infusions and drugs. The DAX-listed group announced on Tuesday evening in Bad Homburg that the forecast range for organic growth in sales would be raised by one percentage point to between 4 and 7 percent.

Adjusted for currency effects, earnings before interest and taxes (EBIT) are now expected to increase by 6 percent to 10 percent. The previous range had been 4 to 8 percent. The increase in the forecast for the Group is based on improved prospects for the subsidiary Fresenius Kabi, which is one of the leading providers of clinical nutrition, intravenous drugs, infusions, medical devices and biopharmaceuticals./zb/he